BeOne Medicines (BEIGF) Research & Development (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Research & Development data on file, last reported at $541.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $541.2 million, up 12.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 11.68% YoY), and the FY2025 annual result was $2.1 billion, up 9.86% from the prior year.
• Research & Development slipped to $541.2 million in Q1 2026 per BEIGF's latest filing, from $615.4 million in the prior quarter.
• Over five years, Research & Development peaked at $615.4 million in Q4 2025 and troughed at $378.2 million in Q2 2022.
• A 5-year average of $474.1 million and a median of $460.6 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 180.18% in 2022, then rose 4.61% in 2025.
• A 5-year view of Research & Development shows it stood at $446.0 million in 2022, then gained by 10.75% to $494.0 million in 2023, then grew by 9.72% to $542.0 million in 2024, then climbed by 13.54% to $615.4 million in 2025, then dropped by 12.06% to $541.2 million in 2026.
• Business Quant data shows BEIGF's Research & Development at $541.2 million in Q1 2026, $615.4 million in Q4 2025, and $523.7 million in Q3 2025.